Earnest Partners 13F: Cuts CRL Stake by $3.8M
Earnest Partners trimmed its stake in Charles River Laboratories by 1.7%, now holding 971,366 shares.
Reviewed by automated data checks against the source filing. How we make and check alerts
Earnest Partners sold 16,893 shares from its stake in Charles River Laboratories International, Inc. ($CRL), a 1.71% decrease, according to a 13F filing with the SEC dated May 15, 2026. It reported 971,366 shares worth $220.30 million at the end of the quarter.
Since the filing, $CRL is up 6.3% after 1 week, up 24.9% after 1 month and up 99.0% to date (from the $150.85 close on May 15, 2026).
Find the original: Earnest Partners 13F filings on SEC EDGAR
CRL
Charles River Laboratories International, Inc.
Key Points
- Earnest Partners reduced its stake in Charles River Laboratories by 16,893 shares, a 1.7% decrease, now holding 971,366 shares worth $219.1 million.
- Charles River Laboratories has a market cap of $10.39 billion and a forward P/E ratio of 17.53, with shares trading near $225.57 as of Tuesday.
- Insiders and analysts are active, with recent insider trades and multiple analysts maintaining 'buy' ratings, including Morgan Stanley's upgrade to a $220 target on June 17, 2026.
Get $CRL trade alerts by text
We text you when insiders, Congress or big funds trade $CRL. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Charles River Laboratories International, Inc. alert may contain errors. Disclosures
Earnest Partners recently trimmed its stake in Charles River Laboratories International, Inc. (NYSE:CRL). According to its latest SEC filing, the firm reduced its holdings by 16,893 shares, representing a 1.7% decrease. Earnest Partners now holds 971,366 shares valued at approximately $219.1 million as of the end of the reporting period.
What Changed in Earnest Partners' Charles River Laboratories Position
Earnest Partners decreased its position in Charles River Laboratories by 1.7%, selling 16,893 shares. This adjustment brings their total holdings to 971,366 shares, valued at about $219.1 million. This move reflects a strategic decision by the firm to slightly reduce its investment in the company.
Other Institutional Activity in Charles River Laboratories
Several other institutional investors have also been active in Charles River Laboratories. BlackRock, Inc. increased its stake by 104,746 shares, now owning 3,859,100 shares worth approximately $665.7 million, a 2.8% increase. FMR LLC significantly boosted its holdings by 1,722,334 shares, resulting in 3,456,244 shares valued at $596.2 million, marking a 99.3% increase. Vanguard Capital Management LLC opened a new position with 3,202,204 shares, valued at about $552.4 million. In contrast, Invesco Ltd. reduced its holdings by 298,898 shares, a decrease of 11.1%, leaving them with 2,397,252 shares worth $413.5 million.
Charles River Laboratories International, Inc. Stock Down 18.4%
On Tuesday, shares of Charles River Laboratories (NYSE:CRL) traded near $225.57. The company has a market capitalization of approximately $10.39 billion and a forward P/E ratio of 17.53. The stock's beta is 1.449, indicating higher volatility compared to the market. Over the past 52 weeks, the stock has ranged from a low of $144.26 to a high of $228.88. The 50-day moving average is $176.75, while the 200-day moving average is $178.97. The company's debt-to-equity ratio stands at 102.55.
Recent Earnings
Charles River Laboratories reported revenue of approximately $4.03 billion, reflecting a modest growth of 1.2%. However, the company faced challenges with a net margin of -4.59% and a return on equity of -5.87%. The next earnings report is scheduled for August 5, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 analysts raised price targets.
-
EPS & revenue
EPS beat estimates by 5.0%. Revenue beat estimates by 0.9%.
-
Profit surprise
EBITDA missed by 6 percent. Operating income missed by 22 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
1 upgrade, 2 target raises.
-
Earnings quality
Gross margin down 4.2 points. Operating margin up 4.5 points. Positive free cash flow.
Earnings Call Summary
Charles River delivered first quarter earnings of $2.06 per share, beating expectations of $1.96, with revenue of about $996 million slightly above consensus. The company faced planned headwinds from animal supply costs and timing issues, but management expressed confidence that these would ease in coming quarters. New CEO Birgit Girshick outlined a strategy called Pathway to Purpose focused on modernizing operations, improving client relationships and driving cost savings of over $100 million this year.
Guidance Charles River reaffirmed full year earnings growth guidance of 5 to 10 percent, expecting around $10.80 to $11.30 in earnings per share. They project significant operating margin expansion of 120 to 150 basis points in 2026, driven mainly by cost savings and completed acquisitions.
Fine but not compelling. Acceptable results that likely do not create a meaningful forward reset.
Insider Buying and Selling at Charles River Laboratories International, Inc.
Recent insider activity at Charles River Laboratories included several transactions on June 5, 2026. Shannon Parisotto, Chief Executive Vice President of Discovery and Safety Assessment, sold 1,529 shares and also purchased the same amount. CEO Birgit Girshick sold and bought 3,386 shares. James Foster, another insider, sold and purchased 183,361 shares.
Analysts Set New Price Targets
Analysts have been adjusting their views on Charles River Laboratories. On June 17, 2026, Morgan Stanley upgraded the stock to a 'buy' rating with a price target of $220. CLSA also upgraded it to 'buy' with a $219 target on May 29, 2026. Barclays maintained its 'buy' rating with a $220 target on May 8, 2026. The consensus rating is a 'buy', with a mean target price of $215.33 among 15 analysts.
About Charles River Laboratories
Charles River Laboratories International, Inc. is a leading provider of drug discovery and development services. Headquartered in Wilmington, Massachusetts, the company operates globally, offering a range of services including drug safety testing, research models, and manufacturing solutions. Under the leadership of CEO Birgit Girshick, Charles River supports pharmaceutical and biotechnology firms in advancing their research and development efforts. The company employs approximately 18,300 people and is a key player in the healthcare sector, specifically within diagnostics and research.
Bottom Line
Earnest Partners' decision to trim its stake in Charles River Laboratories is a notable move, reflecting a slight shift in their investment strategy. Investors often track such changes to gauge institutional sentiment. It's important to remember that 13F filings are backward-looking and may not represent current positions. Charles River Laboratories continues to attract attention from both insiders and analysts, highlighting its significance in the healthcare sector.
Related Filing Alerts
Source: Earnest Partners's 13F filing on $CRL (May 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Earnest Partners 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts